POSTN and melanoma: In contrast, the expression of POSTN in in-transit melanoma from irAE-developed patients before administration of nivolumab (Figure 2B) and in-transit melanoma from non-irAE-developed patients (Figure 2C) was low in fibroblasts distributed in peritumoral lesions.